+64.3%
GSK vs IVZ
+147.9%
-83.6%
-28.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | IVZ | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.2% | -0.8% | -0.4% | -1.2% |
| 7D | -1.1% | -2.8% | +1.7% | -1.0% |
| 30D | +7.8% | -2.2% | +10.0% | +7.9% |
| 3M | +0.3% | -8.1% | +8.4% | +0.7% |
| 6M | +3.4% | +3.8% | -0.3% | +3.0% |
| YTD | +5.9% | +11.5% | -5.6% | +4.7% |
| 1Y | +8.2% | +23.7% | -15.5% | +6.4% |
| All | +64.3% | +147.9% | -83.6% | +57.0% |
Cumulative growth
Daily Returns
Daily percentage return beside IVZ.
Daily Out/Under-Performance
Portfolio return minus IVZ return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × IVZ return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded IVZ wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling